research use only

Avatrombopag TpoR agonist

Name: Avatrombopag
SKU: S6624
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S6624

Avatrombopag (AKR-501,E5501,YM477) is an orally administered, small-molecule thrombopoietin receptor (c-Mpl) agonist which increases platelet number, but not platelet activation.

Chemical Structure

Molecular Weight: 649.65

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: Purity: 99.96%

99.96

Related Targets	Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor TNF-alpha ROS Parasite PD-1/PD-L1 TLR Prostaglandin Receptor IFN CXCR Nrf2 NOS CCR NLRP3 eIF STING AhR IL Receptor Complement System IRAK β-lactamase IDO/TDO PGES FKBP NADPH-oxidase
Related Products	Butyzamide

Chemical Information, Storage & Stability

Molecular Weight	649.65	Formula	C₂₉H₃₄Cl₂N₆O₃S₂	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	570406-98-3	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	AKR-501,E5501,YM477			Smiles	C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl

Solubility

In vitro
Batch:

DMSO : 20 mg/mL (30.78 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05772546	Recruiting	Gastrointestinal Cancer\|Gastrointestinal Neoplasms\|Chemotherapy-Induced Thrombocytopenia	Hanny Al-Samkari MD\|Swedish Orphan Biovitrum\|Massachusetts General Hospital	November 1 2023	Phase 2
NCT04312789	Withdrawn	Platelet Disorder	Ayman Saad\|Sobi Inc.\|Ohio State University Comprehensive Cancer Center	December 2022	Phase 2
NCT05518331	Recruiting	Refractory Aplastic Anemia	Institute of Hematology & Blood Diseases Hospital China\|Peking University People''s Hospital\|Xiyuan Hospital of China Academy of Chinese Medical Sciences\|Second Hospital of Shanxi Medical University\|First Affiliated Hospital of Harbin Medical University\|The First Hospital of Hebei Medical University	June 1 2022	Not Applicable
NCT05218226	Recruiting	Chemotherapy-induced Thrombocytopenia\|Avatrombopag	Institute of Hematology & Blood Diseases Hospital China\|Tianjin Medical University Cancer Institute and Hospital\|Tianjin Medical University Second Hospital\|Tianjin Third Central Hospital\|Tianjin People''s Hospital\|Henan Cancer Hospital\|The Second Affiliated Hospital of Kunming Medical University	February 10 2022	Phase 2
NCT04949009	Unknown status	Primary Immune Thrombocytopenia	Shandong University	March 1 2021	--
NCT04609891	Completed	Thrombocytopenia	Anhui Provincial Cancer Hospital	May 26 2020	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):